Kornimate/medical-research-clean huggingface dataset:
characterizing knee pain and response to surgery using local biomarkers

Conditions: Inflammation

Summary: the diagnosis and monitoring of clinically-significant pathologies of the knee remains challenging, and it is unknown why only some injuries become painful or respond to surgical intervention. the limitations of diagnostic magnetic resonance imaging result in arthroscopy that is not always beneficial. elucidation of biochemical pathways underlying pain in this condition may aid patient selection for surgery and provide pharmacotherapeutic targets. cytokines or a novel yet uncharacterized protein may be involved in pain following meniscus injury and diagnostic cytokine assay may help physicians differentiate patients that may benefit from arthroscopy from those that may not. additionally, evaluating post-operative biochemical profiles may provide a method of monitoring surgical outcome and understanding post-operative continuation or remission of pain.

lavage of the operative and contralateral knee for comparison are performed under anesthesia prior to arthroscopy by the infusion of 10cc sterile saline into the knee joint followed by the immediate withdrawal into the syringe, and storage at -80°c in a tube containing a protease inhibitor. at 12wk post-operative a 10cc lavage is performed on the knee that underwent surgery. clinical findings for each sample are quantified using gold-standard symptom severity questionnaires. the specimens will be analyzed for 31 potential biomarkers using a multiplexed immunoassay panel, the results of which will be compared with pre- and post-operative clinical findings and radiographic imaging. plans do not currently include microarray analysis, but this may be later included.

Eligibility criteria:
inclusion criteria: •adult patients with knee pain (acute or chronic) who had failed conservative treatment and elected for arthroscopic management. indications for surgery included the presence of mechanical symptoms on history, a physical examination positive for mcmurray's maneuver or joint line tenderness or both, absence of severe joint space narrowing on plain radiography, and the presence of grade iii signal changes on mri in an anatomic location consistent with the history and physical examination. exclusion criteria: * less than 18 years old. * recent (within three months) intra-articular corticosteroid injection and past or current medical history of autoimmune disease (i.e. rheumatoid arthritis). * in addition, no patients involved in a worker's compensation claim or personal injury litigation were enrolled in the study.
cognitive and emotional factors relation to treatment adherence in asthmatic patients in upper egypt

Conditions: Bronchial Asthma; Adherence, Medication

Summary: non-adherence to controller therapy is one of the main reasons of poor asthma control. adherence to medication in different studies range between 30 and 70% . several factors related to the disease, to the patient, treatment or physician- patient relationship

non-adherence to controller therapy is one of the main reasons for poor asthma control. adherence to medication in different studies ranges between 30 and 70%. several factors related to the disease, to the patient, treatment, or physician-patient relationship have been identified to be related to adherence in asthma and other diseases. according to the self-regulation theory, medication beliefs and illness perception are associated with treatment adherence. beliefs about illness, the necessity, and the concerns (addition and side effects) of the treatment have been identified as the two most important elements in the proposed theory. other factors that impact treatment adherence are the perceived efficacy of medicines, cost of therapy, complex dosing regimens, patient's level of education, and cultural beliefs. evaluating the beliefs about asthma medication, and cognitive and emotional perceptions may help to identify patients with poor adherence to treatment in clinical practice. that would guide additional attention helping to increase the likelihood of taking asthma medication appropriately. however, only limited information is available on treatment adherence in egyptian people especially in upper egypt. furthermore, evidence identifying medication beliefs, and cognitive or emotional factors associated with asthma medication adherence among egyptian people in upper egypt is currently not available

Eligibility criteria:
inclusion criteria: 1. able to understand and provide informed consent. 2. age ≥18y at the time of study enrollment. 3. provider diagnosed asthma and prescribed maintenance ics treatment and as needed bronchodilator for at least one month exclusion criteria: 1. any other medical condition that confers greater illness morbidity than asthma (e.g., active cancer) 2. severe psychopathology (e.g., schizophrenia) 3. apparent cognitive or language deficit 4. patients with associated other chronic chest diseases
detecting urinary retention after child birth with a ultrasound scanner

Conditions: Urinary Retention

Summary: the purpose of this study is a systematical registration of ultrasound measurements and urinary volume after catheterization. based on these pairs of measurements we will calculate the reliability of ultrasound compared with catheter volume.


Eligibility criteria:
inclusion criteria: * women with suspected urinary retention

Keywords: urinary retention child birth catheterization ultrasound
a clinical study of sacituzumab tirumotecan (mk-2870) in patients with bladder cancer (mk-2870-027)

Conditions: Non-Muscle Invasive Bladder Cancer

Summary: the goal of the study is to learn about the safety of sacituzumab tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. researchers will then choose a dose level of sacituzumab tirumotecan to use in future studies to learn how well the drug works.


Eligibility criteria:
inclusion criteria: the key inclusion criteria include but are not limited to the following: * has recurrent low-grade (ta) non-muscle invasive bladder cancer (nmibc) in the bladder * must have visible tumor by cystoscopy within 12 weeks prior to first dose * has intermediate-risk nmibc defined as 1 or more of the following risk factors: * multiple tumors * \>1 occurrence of low-grade nmibc within 1 year of the current diagnosis at screening * early recurrence (\<1 year) of the initial diagnosis of low-grade disease * solitary tumor \>3 cm * failure of prior intravesical treatment * an eastern cooperative oncology group (ecog) performance status of 0 to 2 assessed within 14 days prior to first dose exclusion criteria: the key exclusion criteria include but are not limited to the following: * newly diagnosed low-grade non-muscle invasive bladder cancer (ta nmibc) in the bladder * past or current history of high-grade (ta or t1 or cis) nmibc, muscle invasive bladder cancer (mibc) or metastatic urothelial carcinoma (uc) * has a condition that would prohibit normal voiding (or hold bladder voiding for 1 to 2 hours) * has history of documented severe dry eye syndrome, severe meibomian gland disease, and/or blepharitis, or severe corneal disease that prevents and/or delays corneal healing * has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, chron's disease, ulcerative colitis, or chronic diarrhea) * has uncontrolled, significant cardiovascular disease or cerebrovascular disease * known additional malignancy that is progressing or has required active treatment within the past 3 years * history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.

Keywords: non-muscle invasive bladder cancer low grade intermediate risk recurrent low-grade
nogo for an overactive bladder

Conditions: Overactive Bladder; Nocturia

Summary: this is a double-blind, randomized and placebo-controlled study to evaluate the safety and effectiveness of nogo, a standardized extract from angelica archangelica, on overactive bladder


Eligibility criteria:
inclusion criteria: * suspected or diagnosed with overactive bladder (average ≥ of 1.5 nocturnal voids per night and/or less then 2 hours between voids at least half time of the day (question 2 ipss) exclusion criteria: * high alcohol consumption (males \> 3 beers/day (36 g alcohol), females \>2 beers/day -- * (24 g alcohol), but we take weekly average. * abnormal urinary findings suggestive of urinary tract infection, significant hematuria or glucosuria requiring further evaluation. * chronic incontinence. * recurrent urinary tract infections (3 or more times per year). * pregnancy, lactation, last child born at least one year before, uterine prolapse, histerectomy * surgical treatment for bladder outlet obstruction/bph performed within the past 6 months. moderate to severe prostate hyperplasia (ipss questionnaire). * medical history or active conditions which, in the opinion of the principal investigator (pi) and physicians participating in the study would prohibit participation in the study. this includes, but is not limited to: diabetes, cancer, renal failure, cirrhosis or chronic liver disease, pancreatic diseases, recent (\<6 months) myocardial infarction or unstable coronary artery disease. * psychiatric diseases and medication. * use of nogo or other products containing a. archangelica extract within the previous 2 months prior to randomisation. * known allergy to compound or any other ingredients of nogo. * supplements like pumpkin seeds, natural products with diuretic effect. not exclusion if they have a wash out period. * receipt of an investigational product within 30 days prior to enrolment or expected receipt during this study.
simultaneous fluoroscopic and endoscopic examination of the oropharyngeal phase of deglutition

Conditions: Dysphagia

Summary: to correlate findings between two commonly-used types of swallowing studies: videofluoroscopy and flexible endoscopic evaluation of swallowing (fees).

the specific aim of this study is to correlate findings between two commonly-used types of swallowing studies: videofluoroscopy and flexible endoscopic evaluation of swallowing (fees). specifically, the timing of swallowing events will be correlated between teh two studies. in addition, the pharyngeal constriction ratio (a validated measure of pharyngeal strength on videofluoroscopy) will be compared with the pharyngeal squeeze maneuver (an assessment of pharyngeal strength on fees), with the hypothesis that there will be a strong correlation between pcr and pharyngeal squeeze.

Eligibility criteria:
inclusion criteria: * complaints of dysphagia * scheduled to undergo videofluoroscopy * able to tolerate both videofluoroscopic evaluation of swallowing and fees exclusion criteria: * age less than 18 * contraindications to videofluoroscopy (reaction to barium, possible pregnancy) * contraindications to fees (bilateral obstructing nasal pathology or nasopharyngeal stenosis) * specific/vulnerable populations (children, mentally handicapped, pregnant women, fetuses, prisoners, cognitive impairment, life-threatening disease, social or economic disadvantage)

Keywords: dysphagia videofluoroscopy flexible endoscopic evaluation
prevalence and screening of abdominal aortic aneurysms among men with coronary artery disease

Conditions: Abdominal Aortic Aneurysm

Summary: the purpose of this study is to investigate the prevalence of abdominal aortic aneurysms (aaa) among male patients with coronary artery disease (cad) verified in coronary angiography. ethiology of aaa is known to be common with atherosclerotic arterial diseases (coronary artery disease, peripheral artery disease and carotid artery disease), so the hypothesis is that aaa should be more common among these cad patients, thus making screening of these patients (for aaa) more cost-efficient. study will be carried out as a multi-center prospective screening study. data will be collected in north karelia central hospital, kuopio university hospital and tampere university hospital. data consists of 200 consecutive coronary angiography patients in each hospital, resulting in 600 patients in total. all male patients with diagnosed cad will be recruited for the study and screened for aaa with ultrasound. nevertheless, patients with previously known aaa will be excluded from the study.


Eligibility criteria:
inclusion criteria: * male patients with coronary artery disease exclusion criteria: * patient's denial to participate * female gender * already diagnosed or treated abdominal aortic aneurysm
secondary prevention in cardiovascular disease by a nursing guided program (spring)

Conditions: Acute Coronary Syndrome; Nutrition; Physical Activity; Secondary Prevention

Summary: design: controlled clinical trial with single randomization, unmasked, open and multicentric. centers: university hospital of a coruña and university hospital of ferrol condition to study: acute coronary syndrome (acs). intervention:monitored outhospital not inhospital supervised. main objective: to determine the incidence of major adverse events (total mortality, new acs, coronary revascularization, all-cause hospitalization) during the one-year period after hospitalization for acs.

the spring study aims to learn whether a remote, nurse-guided secondary prevention program reduces adverse events in patients who suffer an infarction during the subsequent one-year period. the spring study focuses not only on adverse events but also on the patients' state of life in terms of diet, physical exercise, emotional state, tobacco use, and adherence to medical treatment. nursing is a profession in charge of preserving the health of patients, which is why the remote secondary cardiovascular prevention program of this study is coordinated by a nurse.

Eligibility criteria:
inclusion criteria: * all patients who have suffered an acs in the health area of a coruña or ferrol from the beginning of the study inclusion period until reaching the fixed sample size. * ages between 18 and 75 years. * patients with ability to read and understand the participation sheet in the study. * patients signing informed consent to participate in the study. * patients living in the health care area of huac or huf. exclusion criteria: * patients who are dependent for the basic activities of daily living (badl) or who suffer from severe cognitive impairment (which makes reliable anamnesis impossible). * patients with a left ventricular ejection fraction (lvef) less than or equal to 35%. * patients with a nyha iii / iv score and / or the canadian cardiovascular association (ccs) scale of iv.
comparison of dynamic versus static lag screw modes for cephalomedullary nails used to fix intertrochanteric fragility fractures

Conditions: Hip Fractures

Summary: the objective of this study is to compare the failure rate between two modes of fixing the lag screw of the cephalomedullary nail. the sample studied will be patients who have been diagnosed with a fragility intertrochanteric fracture. investigators hypothesis is that the dynamic mode will have a lower failure rate compared to the static mode.

intertrochanteric fragility fractures are one of the most frequent fractures in the elderly . they produce great disability and complications in our patients and they are recognized worldwide as a major public health problem. the treatment that presents the best results is surgical treatment, since it reduces the mortality of the patients and allows early loading . thus, avoids secondary complications to the prostration state such as pneumonia, bedsores, pulmonary embolisms, among others. currently, the treatment that has shown the best clinical and biomechanical results is osteosynthesis with a cephalomedullary nail, which despite having good results is not free from complications such as implant failure, loss of femoral offset. changes are constantly made in the design and surgical techniques of these implants in order to decrease the rate of complications. this study will particularly assess whether there is any difference in the complication rate between dynamic versus static lag screw modes. biomechanical studies that compare these two lag screw modes show that axial and lateral stiffness of the femur-nail construction is greater in static mode than in dynamic modes and the torsional stiffness is greater in dynamic mode than in static modes. there are no studies comparing the clinical results of these two variants.

Eligibility criteria:
inclusion criteria: * low energy mechanism * hip fracture classified as 31.a1.2 - 31 a1.3 and 31.a2 in the ao classification (year 2018) exclusion criteria: * a fracture due to malignancy * previous contralateral fracture * inability to walk before the fracture * an inability to comply with rehabilitation * follow-up of less than 6 months

Keywords: hip fractures intertrochanteric fractures cephalomedullary nails cut-out cut through
clinical trial to assess the safety and efficacy of intravenous administration of allogeneic adult mesenchymal stem cells of expanded adipose tissue in patients with severe pneumonia due to covid-19

Conditions: Sars-CoV2

Summary: phase i/ii clinical trial to evaluate the safety and efficacy of allogenic adipose tissue-derived mesenchymal stem cells expanded in patients with severe covid-19 pneumonia


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 2. clinical diagnosis of pneumonia, severe or critical, caused by covid-19 infection 3. life expectancy \> 48 hours. 4. commitment to use a contraceptive method of proven efficacy in both men and women during the duration of the clinical trial. exclusion criteria: 1. coinfection with other viruses or bacteria (hiv, tuberculosis, influenza virus, adenovirus or other respiratory infections, active infection by hbv or c). 2. history of multiple allergies, including allergy to penicillin or other blactams. 3. pregnant and lactating women. 4. patients with malignant tumors or hemopathies or any state of immunosuppression considered as severe. 5. patients with autoimmune diseases. 6. chronic heart failure with ejection fraction less than 30%. 7. any other condition for which, in the opinion of the main investigator, the subject is considered not to be in compliance with the study.
efficacy and tolerability of rimegepant for the prevention of migraine in adults with history of inadequate response to oral preventive medications

Conditions: Migraine

Summary: this study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications


Eligibility criteria:
inclusion criteria: 1. migraine attacks present for more than 1 year with the age of onset prior to 50 years of age. 2. migraine attacks, on average, lasting about 4 - 72 hours, if untreated. 3. 4 to 14 migraine days per month, on average, across the 3 months prior to the screening visit (month is defined as 28-days for the purpose of this protocol). 4. less than15 headache days (migraine or non-migraine) per month in each of the 3-months prior to the screening visit and throughout the screening phase. 5. subjects must be able to distinguish migraine attacks from tension/cluster headaches. prior inadequate response, within 10 years of the screening visit, to agents across 2-4 categories of recognized, orally-administered, migraine-preventive medications where at least one example of prior inadequate response is due to lack of efficacy or prior intolerance (not contraindication). exclusion criteria: 1. history of cluster headaches, basilar migraine (migraine with brainstem aura), or hemiplegic migraine. 2. current medication overuse headaches. 3. 15 or more headache days (migraine or non-migraine) per month in any of the 3-months prior to the screening visit or during the first 28- days of the observation phase. 4. inadequate response (due to lack of efficacy, prior intolerance, or contraindication) to agents across \> 4 categories of recognized, orally administered, migraine-preventive medications. 5. active chronic pain syndrome (such as fibromyalgia, chronic pelvic pain, complex regional pain syndrome \[crps\]). 6. other pain syndromes (including trigeminal neuralgia), dementia, or significant neurological disorders (other than migraine) that, in the investigator's opinion, interfere with study assessments of safety or efficacy.

Keywords: migraine prevention headache headache prevention migraine prevention in adults with inadequate response to oral preventative medications
the use of a platform wound device for reducing infection

Conditions: Wounds and Injury; Burn Wound; Infection Wound

Summary: this study will evaluate the safety and efficacy of a novel platform wound device (pwd) in its delivery of a local antibiotic, 0.1% gentamycin cream, to prevent or treat infection in torso and extremity wounds. the hypothesis is that the pwd will be a safe and effective method to provide topical antibiotics to a torso or extremity wound, non-inferior to the current standard of care. this treatment will reduce or rapidly eradicate infection.

this is a prospective, randomized, controlled clinical trial comparing the use of a platform wound device as compared to standard of care to prevent or eliminate infection in torso and extremity wounds. patients 18-85 years of age admitted for treatment of open wound(s) will be screened for inclusion criteria and asked to consent to participate in the randomized study. the first 10 patients will be treated with the pwd + gentamicin and will serve as a safety subset. baseline measurement of serum antibiotic concentraion will be taken prior to pwd placement and one day after. following the safety subset, 50 patients will be randomized to standard of care or to a single application of the pwd + gentamicin. baseline assessments will be completed on day 0, including screening, pre-procedure wound evaluation, imaging, assessments, and specimen collection. follow-up assessments will be completed and data gathered at days 1,2,3 and 4. all data collected of the study participants will be used to evaluate the pwd delivery of antibiotic.

Eligibility criteria:
inclusion criteria: 1. age greater or equal to 18 and age less than or equal to 85 2. open wound up to 500cm2 in area with evidence of infection 3. exposure of deep dermis, subcutaneous tissue, muscle, fascia, tendon, or bone exclusion criteria: 1. pregnancy 2. prisoner 3. active malignancy, steroid use, or immunosuppressive therapy 4. open fracture intimately involved with wound 5. underlying osteomyelitis 6. hardware or prosthetic exposure within wound 7. exposure of major named vessels or nerves 8. known allergy to gentamicin or other aminoglycosides